June 1, 2012
New Class of Cancer Drugs May Be Less Toxic
The experimental treatment, called T-DM1, is a harbinger of a new class of cancer drugs that may be more effective and less toxic than many existing treatments. By harnessing antibodies to deliver toxic payloads to cancer cells, while largely sparing healthy cells, the drugs are a step toward the “magic bullets” against cancer first envisioned […]
Tags: Adcetris, American Society of Clinical Oncology, Dr. Edith Perez, experimental treatment, NY Times, Paul Ehrlich, Seattle Genetics